Reuters logo
BRIEF-Vifor Pharma, ChemoCentryx announce expansion of Avacopan agreement
February 14, 2017 / 12:22 PM / 10 months ago

BRIEF-Vifor Pharma, ChemoCentryx announce expansion of Avacopan agreement

Feb 14 (Reuters) - ChemoCentryx Inc

* Vifor Pharma and ChemoCentryx announce expansion of avacopan agreement for rare renal diseases

* ChemoCentryx Inc - vifor pharma has gained rights to commercialize avacopan in Asia, including Japan and Middle-East

* ChemoCentryx Inc - ChemoCentryx retains all rights in united states and china

* ChemoCentryx Inc - agreement gives Vifor Pharma rights to commercialize Avacopan for orphan, rare renal diseases in all markets outside U.S. , China

* ChemoCentryx Inc - will receive an upfront cash commitment of usd 20 million in return for new rights, plus tiered double-digit royalties on potential net sales

* ChemoCentryx Inc - upfront cash commitment is in addition to usd 85 million upfront paid under original May 2016 licensing agreement Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below